These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 10500344

  • 1. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A.
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP, Schuster P.
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [Abstract] [Full Text] [Related]

  • 3. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G.
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE.
    Am J Cardiol; 1999 May 06; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract] [Full Text] [Related]

  • 7. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE, Gupta R, Rajendran S, Luu J, French JK, Juergens CP.
    Cardiovasc Ther; 2016 Oct 06; 34(5):330-6. PubMed ID: 27327862
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
    King S, Short M, Harmon C.
    Vascul Pharmacol; 2016 Mar 06; 78():10-6. PubMed ID: 26187354
    [Abstract] [Full Text] [Related]

  • 10. GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?
    Musumeci G, Baroni M, Rossini R.
    Curr Vasc Pharmacol; 2012 Jul 06; 10(4):443-7. PubMed ID: 22339252
    [Abstract] [Full Text] [Related]

  • 11. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
    Kleiman NS.
    Coron Artery Dis; 1998 Jul 06; 9(9):603-16. PubMed ID: 9861523
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Current issues with glycoprotein IIb-IIIa antagonists.
    Schneider DJ.
    Curr Drug Targets; 2011 Nov 06; 12(12):1813-20. PubMed ID: 21718238
    [Abstract] [Full Text] [Related]

  • 17. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.
    Störk T, Fröhlich E, Möckel M.
    Lancet; 2001 Dec 08; 358(9297):1996-7. PubMed ID: 11747950
    [No Abstract] [Full Text] [Related]

  • 18. A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.
    Vakili BA, Kaplan RC, Slater JN, Sherman W, Ravi KL, Green SJ, Sanborn TA, Brown DL.
    Am J Cardiol; 2003 Apr 15; 91(8):946-50. PubMed ID: 12686333
    [Abstract] [Full Text] [Related]

  • 19. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
    Gowda RM, Khan IA, Vasavada BC, Sacchi TJ.
    Am J Ther; 2004 Apr 15; 11(4):302-7. PubMed ID: 15266223
    [Abstract] [Full Text] [Related]

  • 20. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Gibson CM, Moynihan JL, Al-Mousa EN, Campsey M, Gandhi R, Murphy S, Mattson S, Ryan KA, Mesley R, Swanson J, Arshad MN, Marble SJ.
    J Thromb Thrombolysis; 1999 Jun 15; 7(3):287-302. PubMed ID: 10375390
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.